Blank

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

China Bio-Med Regeneration Technology Limited

中國生物醫學再生科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8158) PROPOSED CHANGE OF COMPANY NAME

The Board proposes to change the name of the Company from "China Bio-Med Regeneration Technology Limited 中 國 生 物 醫 學 再 生 科 技 有 限 公 司 " to "China Regenerative Medicine International Limited 中國再生醫學國際有限公司".
The proposed Change of Company Name is subject to (i) the passing of a special resolution by shareholders approving the Change of Company Name at the forthcoming EGM; and (ii) the Registrar of Companies in the Cayman Islands approving the Change of Company Name.
A circular containing, among other things, the information relating to the proposed Change of Company Name and a notice convening the forthcoming EGM will be despatched to Shareholders as soon as practicable. The Company will make further announcement(s) on the effective date of the proposed Change of Company Name and the consequential change of the stock short name of the Company upon the proposed Change of Company Name becoming effective.

PROPOSED CHANGE OF COMPANY NAME

The board (the "Board") of directors (the "Directors") of China Bio-Med Regeneration Technology Limited (the "Company" and together with its subsidiaries, the "Group") proposes to change the name of the Company from "China Bio-Med Regeneration
Technology Limited 中國生物醫學再生科技有限公司" to "China Regenerative Medicine
International Limited 中國再生醫學國際有限公司" (the "Change of Company Name").

- 1 -

Conditions for the Change of Company Name

The proposed Change of Company Name is subject to (i) the passing of a special resolution by shareholders of the Company (the "Shareholders") approving the Change of Company Name at a forthcoming extraordinary general meeting of the Company (the "EGM"); and (ii) the Registrar of Companies in the Cayman Islands approving the Change of Company Name.
Subject to the satisfaction of the above conditions, the new name of the Company will take effect from the date on which the special resolution to effect the change of name is passed at the EGM, and will be evidenced by a Certificate of Incorporation on Change of Name issued by the Registrar of Companies in the Cayman Islands. The Company will carry out all necessary registration and/or filing procedures with the Registrar of Companies in the Cayman Islands and the Companies Registry in Hong Kong.

Reasons for the Change of Company Name

Since early 2013, we have participated in stem cell research and development through the sponsorship collaboration with the University of Hong Kong in "stem cell development in anti-aging matters". In addition, we entered a collaboration agreement with the University of Oxford specifying in "enabling technologies for stem cell therapy and tissue engineering" in November 2013. On 16 December 2014, the Company entered another new 5-year collaboration agreement with the University of Oxford to enhance the Group's research capacity and capability in regenerative medical technology, hoping that this new collaboration will bring some breakthrough and solved major unmet clinical issues in stem cells related research and development which will ultimately lead to the development of stem cell therapy. The Company is also in active negotiation with Hong Kong Science Park, with a view to renting premises there to build a GMP standard stem cell clinical applications centre. With all these collaborations, the Company positions itself to take advantage of stem cell therapy in the near future. Together with our existing production operations for tissue engineering in the PRC, we cover a rather complete spectrum of regenerative medicine. As such the Change of Company Name better reflects our current development.
The Board considers that the Change of Company Name will provide the Company with a new corporate image and to reflect the Company's strategy to diversify the business of the Group.
The Board believes that the new company name can provide the Company with a fresh identity and image which will benefit the Company's future business development and is in the interest of the Company and its shareholders as a whole.

- 2 -

Effects of the Change of Company Name

The Change of Company Name will not affect any rights of the Shareholders. Once the Change of Company Name becomes effective, any issue of share certificates of the Company thereafter will be in the new name of the Company. However, all the existing share certificates in issue bearing the present name of the Company will, after the proposed Change of Company Name having become effective, continue to be evidence of title to such shares and the existing share certificates will continue to be valid for trading, settlement, registration and delivery purposes. There will not be any arrangement for free exchange of the existing share certificates of the Company for new share certificates bearing the new name of the Company.

GENERAL

At the EGM to be convened and held, a special resolution will be proposed for the Shareholders to consider and, if thought fit, approve the proposed Change of Company Name. A circular containing, among other things, information relating to the proposed Change of Company Name together with a notice of the EGM, will be despatched to the Shareholders as soon as practicable.
Further announcement(s) will be made by the Company to inform the Shareholders of the results of the EGM, the effective date of the Change of Company Name and the corresponding change of English and Chinese stock short names of the Company for trading of the Company's shares on The Stock Exchange of Hong Kong Limited as and when appropriate.
By Order of the Board

China Bio-Med Regeneration Technology Limited Dai Yumin

Executive Director

Hong Kong, 29 December 2014

- 3 -

As at the date of this announcement, the executive Directors are Mr. Dai Yumin and Ms. Wang Yurong; the non-executive Directors are Mr. Wong Sai Hung, Professor Deng Shaoping, Mr. Cao Fushun, Mr. Yang Zhengguo, Mr. Ma Long and Mr. Wang Jianjun; and the independent non-executive Directors are Mr. Lui Tin Nang, Mr. Chan Wing Hang, Mr. Pang Chung Fai Benny and Mr. Chan Bing Woon, SBS, JP.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited ("GEM") for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Company Announcement" page of the GEM website at www.hkgem.com for at least seven days from the date of the publication and will be published on the

website of the Company at www.bmregeneration.com.

- 4 -

distributed by